For the first time in nearly 50 years, the U.S. Food and Drug Administration will examine asbestos testing for talc powders and cosmetics at a hearing.
Over the past 50 years, the FDA has relied upon – and often deferred to – industry even as outside experts and consumers repeatedly raised serious health concerns about talc powders and cosmetics, a Reuters investigation found.
An injection to treat forehead wrinkles is set to rival Allergan plc’s Botox after U.S. regulators approved Evolus Inc.’s cheaper treatment, sending the Newport Beach, Calif.-based company’s shares up about 5 percent.
Allergan Plc, best known as the maker of Botox, announced today that it will buy Kythera Biopharmaceuticals, Inc. (KYTH) for approximately $2.1 billion. Kythera is focused on treatments for double […]
One thing about Allergan chief executive Brent Saunders is he doesn’t waste much time. After all, he was personally involved in setting up $97 billion worth of deals last year. The […]